Strategic Initiative

Slingshot members are tracking this corporate initiative:

Neurocrine Biosciences (NBIX) and Xenon Pharmaceuticals(XENE) Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All Licensed Products, as well as Option to Co-Fund XEN901
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Dec 02, 2019
Projected Implementation:
Q4, 2019
Relevance Tracked Until:
Q1, 2020
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Epilepsy, Xen901, Nav1.6 Sodium Channel Inhibitor